OrbiMed Raises $3 Billion for Two New Healthcare Funds, Split Between US-Europe Venture and Asia Growth

OrbiMed, the global healthcare investment firm, announced on October 15, 2026 that it has raised $3 billion in commitments across two new private equity funds: OrbiMed Private Investments X, with over $1.9 billion for U.S. and European life sciences venture capital, and OrbiMed Asia Partners VI, with over $1 billion for healthcare growth equity and venture capital across Asia. For founders, the split defines a clear decision boundary: geography and stage determine which fund is even a candidate.

OrbiMed Raises $3 Billion for New Healthcare Funds

The New York-based firm, which secondary reporting notes holds more than $21 billion in assets under management, framed the dual raise as a continuation of its global strategy. Both funds, according to OrbiMed's announcement, seek to build leading healthcare companies focused on biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. The two vehicles are the tenth and sixth iterations of OrbiMed's long-running private investment and Asia Partners franchises, signaling institutional continuity rather than a new strategy.

OrbiMed's two new funds announced October 15, 2026
Attribute	OrbiMed Private Investments X	OrbiMed Asia Partners VI
Total capital	Over $1.9 billion	Over $1 billion
Geographic focus	U.S. and Europe	Asia
Investment stage	Venture-stage life sciences	Venture capital and growth equity
Target sectors	Biopharmaceuticals, medical devices, diagnostics, technology-enabled healthcare services	Biopharmaceuticals, medical devices, diagnostics, technology-enabled healthcare services

OrbiMed's Fundraising Trend: A Historical Perspective

The $3 billion raise continues a pattern of large, recurring dual-geography fund cycles. In October 2023, OrbiMed announced more than $4.3 billion across OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV, spanning seed stage through growth capital. Its 2021 cycle raised $3.5 billion across predecessor funds including Private Investments VIII and Asia Partners IV.

The predecessor funds' stated parameters illustrate the model's consistency. Private Investments VIII targeted venture-stage opportunities in North America and Europe with investments of $10 million to $100 million across roughly 40 portfolio companies, while Asia Partners IV invested primarily in China and India from venture through growth stage, at similar check sizes across approximately 20 companies. The new funds' naming, regional split and stage structure track that lineage closely, though the 2026 total is smaller than the 2023 raise — which included a royalty and credit vehicle absent from the current announcement.